Utilizing a Stepwise Approach for Nitrosamine Risk Mitigation

The introduction of mandatory nitrosamine testing in 2018 – and subsequent updates to regulatory requirements – pressed drug developers to meet stringent criteria for selectivity and sensitivity. Nitrosamines can develop during both API and drug product manufacturing, leading to potential questions for innovators regarding when to conduct analysis for these impurities.

Join Cambrex expert Todd Sprouse, Associate Director of Analytical Services, as he reviews insights and case studies for how a product-specific, stepwise testing approach can help detect, quantify and control nitrosamine impurities while maintaining cost efficiency.

Key Learnings:

  • Developing a process for evaluating the risk of nitrosamine impurities
  • Evaluating potential for nitrosamine formation in the manufacturing process
  • Determining feasibility of nitrosamine formation utilizing standard nitrosylation conditions
  • Developing analytical methods for quantitation for any nitrosamine impurity
  • Mitigating risk through nitrate testing of APIs, raw materials, and excipients